Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Cancers

Adjuvant Therapy in Resected Adrenocortical Carcinoma: Current Evidence and Patient Selection

  • Lina Pedraza Sanchez1
  • Guilherme Rabinowits1
  • Elio Monsour1
  • Prerna Dogra1
  1. 1Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
Open at sourceDOICite

Abstract

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with recurrence rates of 54–70% following curative-intent resection, even after microscopically complete (R0) surgery. In this review, we summarize the current evidence for adjuvant mitotane, platinum-based chemotherapy, and radiation therapy in resected ACC, and discuss patient selection based on prognostic risk stratification. We also highlight the importance of multidisciplinary management at expert centers, remaining evidence gaps, and future directions including biomarker-driven treatment strategies.

Related

  1. Extent of lymphadenectomy dictates adjuvant chemotherapy benefit in primarily resected esophageal squamous cell carcinoma: a multi-cohort validation
    Yicheng Huang, Xuanhao Lin, Yanhong Lin +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  2. Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
    Xin Xin, Ruoyu Miao
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study
    Juemin Yu, Jialiang Wen, Tao Chen +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  5. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL

Cite

BibTeXRIS
BibTeX
@article{sanchez2026adjuvant,
  title = {{Adjuvant Therapy in Resected Adrenocortical Carcinoma: Current Evidence and Patient Selection}},
  author = {Lina Pedraza Sanchez and Guilherme Rabinowits and Elio Monsour and Prerna Dogra},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18203276},
  url = {https://www.mdpi.com/2072-6694/18/20/3276},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Adjuvant Therapy in Resected Adrenocortical Carcinoma: Current Evidence and Patient Selection
AU  - Lina Pedraza Sanchez
AU  - Guilherme Rabinowits
AU  - Elio Monsour
AU  - Prerna Dogra
PY  - 2026
DA  - 2026/10/11
JO  - Cancers
DO  - 10.3390/cancers18203276
UR  - https://www.mdpi.com/2072-6694/18/20/3276
AB  - Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with recurrence rates of 54–70% following curative-intent resection, even after microscopically complete (R0) surgery. In this review, we summarize the current evidence for adjuvant mitotane, platinum-based chemotherapy, and radiation therapy in resected ACC, and discuss patient selection based on prognostic risk stratification. We also highlight the importance of multidisciplinary management at expert centers, remaining evidence gaps, and future directions including biomarker-driven treatment strategies.
SN  - 2072-6694
ER  -